← board
IPSC
Century Therapeutics, Inc.distress 6/10 · elevated risk$2.12-2%today-28% from 52w high
Oncology 1
Lead: B-cell-mediated autoimmune diseases · target CD19
Revenue
$109M
Liquidity
$217M
Runway
2.3 yrs
Shares 1y
+109%
Price & events
-8.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-6.4%
1W
-12.2%
1M
-6.4%
3M
-12.6%
6M
+232.0%
1Y
-14.5%
2Y
-92.8%
5Y
-90.7%
All
Overview
- Market Cap
- $381.45M
- Volume
- 44.19K
- 52 Week Range
- $0.47 – $2.94
- Total Shares
- 180.35M
- Float Shares
- 97.71M
- Short %
- 13.10%
- % Held by Insiders
- 8.20%
- % Held by Institutions
- 77.92%
- RVOL
- 0.03x
- Beta
- 1.56
Pipeline stages · 1 programs
CNTY-101, IL-2, Lymphodepleting ChemotherapyCD19
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-07-01 | Phase 1 | CNTY-101, IL-2, Lymphodepleting Chemotherapy | R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma | 28 | terminated |
Catalyst news & presentations · 17
- second half of 2027Guided 55%readoutCNTY-813 · Initial clinical data expected in 2H 2027.SEC 8-K
- fourth quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)CNTY-813 · IND submission for CNTY-813, a beta islet cell therapy for type 1 diabetes.SEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 1CNTY-308 · Expected to enter clinic in 2026SEC 8-K
- 2026Guided 40%readoutPhase 1/2CNTY-101 · Updated preliminary clinical data from CARAMEL IST expected in 2026.SEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- as early as 2026regulatory submissionFiled (NDA/BLA)CNTY-813 · IND submission plannedSEC 8-K
- year-end 2025trial initiationsecondaryCNTY-813 · Expected to begin IND-enabling studies by year-end 2025SEC 8-K
- 2025conferencedata presentationsecondaryCNTY-101 · Further ELiPSE-1 data expected to be presented in 2025SEC 8-K
- third quarter of 2025trial initiationsecondaryPhase 1/2CNTY-101 · Initial patient enrollment and dosing in CARAMEL IITSEC 8-K
- mid-2025trial initiationsecondaryPhase 1/2CNTY-101 · CARAMEL Phase 1/2 investigator-initiated trial expected to commence in mid-2025SEC 8-K
- May 2025conferencedata presentationsecondarymultiple preclinical candidates · Presentations at ASGCT 28th Annual Meeting on preclinical pipelineSEC 8-K
- 2025-03-19trial discontinuedCNTY-101 · Early discontinuation of Phase 1 ELiPSE-1 trial in R/R NHLSEC 8-K
- 2025-03-12partnershipBristol-Myers Squibb collaboration terminated; $109.2M revenue recognized in Q1 2025SEC 8-K
- 2025-03-01fda agreementCNTY-101 · First patient dosed in Phase 1 CALiPSO-1 trial in autoimmune diseaseSEC 8-K
- 2H 2024trial initiationsecondaryPhase 1CNTY-101 · Advancing into dose expansion for ELiPSE-1 trialSEC 8-K
- by year-end 2024readoutPhase 1CNTY-101 · Initial clinical data from CALiPSO-1 trialSEC 8-K
- second half of 2024regulatory submissionFiled (NDA/BLA)CNTY-101 · Submit additional regulatory filings for CNTY-101 in autoimmune indicationsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-27MizuhoOutperform
- 2026-04-21HC Wainwright & Co.Buy
- 2026-01-20Piper SandlerOverweight
- 2025-11-17Leerink PartnersOutperform → Market Perform
- 2025-05-16Chardan CapitalBuy
- 2025-04-03HC Wainwright & Co.Buy
Competitors — CD19
Recent news
- 2026-07-22IPSC stock trades steadily as Century Therapeutics updates its pipeline and cash runway - Ad-hoc-news.de
- 2026-07-19IPSC stock trades around recent lows as Century Therapeutics weighs pipeline and cash burn - Ad-hoc-news.de
- 2026-07-14Century Therapeutics (IPSC) Dips 2.7% as Shares Near Key Support Zone - Dividend Stock Picks - dars.gov.et
- 2026-07-14Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses - Yahoo Finance
- 2026-07-09Century Therapeutics abstracts accepted for diabetes conferences - Investing.com
- 2026-07-09Century Therapeutics abstracts accepted for diabetes conferences By Investing.com - Investing.com Nigeria
- 2026-07-09Century Therapeutics abstracts accepted for diabetes conferences - Investing.com
- 2026-07-09Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026 - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.